Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 versus standard of care in relapsed/refractory small cell lung cancer
ChiCTR2600134271Phase 3Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing ABBV-706 with Standard of care comparator (2 arms). Primary endpoints: Objective response and Overall survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600134271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134271.